Tammenoms Bakker Juliet Increases Stake in RxSight, Inc.
Insider Tammenoms Bakker Juliet purchased 37,037 shares of RxSight, Inc. on June 17, 2026.
Key Points
- Tammenoms Bakker Juliet acquired 37,037 shares of RxSight, Inc. on June 17, 2026, without a planned transaction.
- Shares of NasdaqGM:RXST traded near $4.73 on Friday, with a 52-week range between $4.48 and $14.25.
- Analysts like Wells Fargo and Needham have set price targets between $9 and $13, maintaining hold and buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, insider Tammenoms Bakker Juliet purchased 37,037 shares of RxSight, Inc. This transaction was not part of a pre-arranged trading plan, known as a 10b5-1 plan. The details regarding the price and total value of the transaction were not disclosed.
Insider Buying and Selling at RxSight, Inc.
Several insiders, including Tammenoms Bakker Juliet, acquired 37,037 shares each of RxSight, Inc. on June 17, 2026. Other insiders such as Robert Keith Warner, Robert Palmisano, William Link, Shweta Maniar, and Jesse Anderson Corley also participated in these purchases, all without pre-arranged plans.
Other Institutional Activity in RxSight, Inc.
Among institutional investors, BlackRock, Inc. increased its holdings by 482,086 shares, ending with 3,187,092 shares valued at approximately $19.63 million, marking a 17.8% increase. Millennium Management LLC reduced its position by 69,579 shares to 2,059,459 shares, valued at about $12.69 million, reflecting a 3.3% decrease. Artisan Partners Limited Partnership also cut its stake by 98,580 shares, holding 2,058,684 shares worth roughly $12.68 million, a 4.6% decrease. Nomura Holdings Inc. maintained its position with 2,000,060 shares valued at $12.32 million. Meanwhile, No Street GP LP slightly increased its holdings by 25,000 shares to 2,000,000 shares, valued at $12.32 million, representing a 1.3% increase.
RxSight, Inc. Stock Down 32.9%
Shares of RxSight, Inc. (NasdaqGM:RXST) traded near $4.73 on Friday. The company has a market cap of approximately $195.8 million and a forward P/E ratio of -8.45, reflecting its current unprofitability. With a beta of 1.134, the stock has been more volatile than the overall market. Its 52-week range spans from a low of $4.48 to a high of $14.25. The stock's 50-day moving average is $6.09, while the 200-day moving average is $8.36. RxSight maintains a strong liquidity position with a current ratio of 10.2 and a quick ratio of 8.779, alongside a debt-to-equity ratio of 4.05.
$RXST stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
RxSight, Inc. reported revenue of $127.48 million but faced a revenue decline of 18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%, indicating ongoing financial challenges. The next earnings report is expected on August 6, 2026.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a hold rating for RxSight, Inc., with a price target of $9. Needham also maintained its buy rating with a target of $11. Earlier, on March 9, 2026, Stifel had maintained a hold rating with a $9 target. The consensus among seven analysts suggests a mean price target of $8.79.
About RxSight, Inc.
RxSight, Inc. is a healthcare company based in Aliso Viejo, California. It specializes in developing, manufacturing, and selling light adjustable intraocular lenses used primarily in cataract surgeries. The company's flagship product, the RxSight system, allows for post-surgery visual acuity customization through light adjustments. Led by CEO Dr. Ronald M. Kurtz, the company employs 461 people and operates within the medical devices industry.
Bottom Line
The recent insider buying activity at RxSight, Inc. is noteworthy, with several insiders, including Tammenoms Bakker Juliet, acquiring shares. While the company's stock has seen significant volatility, it remains a focus due to its innovative medical technology. Investors should note that the insider transactions and institutional activities are backward-looking and reflect past decisions.
Get RxSight, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RXST, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.